Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

NCT ID: NCT01549977

Last Updated: 2013-12-20

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2012-11-30

Brief Summary

The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo as an add on to stable anti-anginal therapy, on the total exercise time of participants with Chronic Stable Angina.

Detailed Description

This is a phase 2 multicenter, randomized, placebo-controlled double-blind study. This study is comprised of a single-blind placebo run-in qualifying phase lasting approximately 3 weeks and a double-blind treatment phase lasting 12 weeks. A safety follow-up visit is scheduled for 2 weeks after last dose of study drug.

All participants will undergo 3 visits during a 3 week, run-in phase (Days -21 to Day 1). During the run-in phase, all participants will receive single-blind placebo. Two exercise treadmill tests (ETTs) will be conducted using the modified Bruce Protocol at Day -14 and at Day -7. The results from the Day -7 ETT will be considered as Baseline.

A total of approximately 100 participants will be randomized 1:1 to receive either febuxostat 80 mg once daily (QD) or placebo QD in a double-blind treatment for 12 weeks, and 5 more visits.

All participants will complete the Seattle Angina Questionnaire (SAQ) and Euroqol 5 dimension (EQ-5D) quality-of-life measurements at Day 1, Week 6 and Week 12/Early Termination (ET) Visit. The investigator will also rate the overall severity of the participant's angina at each visit based on the Canadian Cardiovascular Society Grading of Angina (CCSGA).

This 12-week phase 2 proof-of-concept study was designed to assess the effect of febuxostat as an add-on to stable anti-anginal therapy on the total exercise time of participants with chronic stable angina and a serum urate ≥5 mg/dL. At this time, Takeda has decided to terminate the study for business reasons.

Conditions

Angina

Keywords

Drug Therapy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Febuxostat 80 mg

Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.

Group Type: EXPERIMENTAL

Febuxostat

Intervention Type: DRUG

Febuxostat tablets

Placebo

Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Febuxostat placebo-matching tablets

Interventions

Febuxostat

Febuxostat tablets

Intervention Type: DRUG

Placebo

Febuxostat placebo-matching tablets

Intervention Type: DRUG

Other Intervention Names

TMX-67; Uloric

Eligibility Criteria

Inclusion Criteria

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

2. The participant or, when applicable, the participant's legally acceptable representative, signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

3. The participant has an serum urate (sUA) ≥5.0 mg/dL.

4. The participant has a history of angina, defined as:

1. Minimum of 3-month history of stable angina (at least 2 episodes of chest pain or anginal equivalent in the past 30 days); AND

2. Receiving at least one chronic anti-ischemic medication(s), including beta blockers, calcium channel blockers and long acting nitrates (doses must be stable for at least 30 days prior to Screening [Day -21]); AND

3. Coronary artery disease, as defined by:

• ≥50 % stenosis of ≥1 major coronary artery confirmed by angiography; OR
• Documented prior myocardial infarction (MI) by enzymes/electrocardiogram (ECG) changes; OR
• Documented myocardial imaging stress test; OR
• Prior history of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) greater than 3 months prior to Screening Day -21.

5. The participant has estimated glomerular filtration rate (eGFR) >30 mL/min by Modification of Diet in Renal Disease (MDRD) at the Screening visit Day -21.

6. The participant has a normal/controlled blood pressure at Day 1/Randomization, as defined by the mean of three sitting blood pressures not exceeding 140/90.

7. The participant is male or female and aged 18 to 85 years, inclusive.

8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.

9. Participant is on stable (30 days) medication doses prescribed for any underlying medical condition (ie; hypertension, angina) and will remain on stable doses throughout the study duration.

10. Participant is able to take, in an ongoing manner, nitroglycerine for anginal symptoms.

11. Symptom-limited exercise duration, during ETT at Day -14 and Day -7, on the modified Bruce Protocol.

12. Exercise duration for the two ETTs at Day -14 and Day -7 did not differ by more than 20% of the longer of the two times, and did not differ by more than 60 seconds. To be confirmed by the Core ECG Lab prior to the subject being randomized.

13. Definite ECG signs of ischemia during the ETT at both Day -14 and Day -7 (i.e., 1 additional mm of horizontal or down-sloping ST-segment depression beyond baseline and ≥1 mm below the isoelectric line) are present in at least one standard ECG lead during ETT. The Day -7 ≥1 mm ST-segment depression must be verified by the Core ECG Lab prior to participant being randomized.

Exclusion Criteria

1. The participant has received any investigational compound within 30 days prior to Screening Day -21.

2. The participant has received allopurinol or febuxostat in a previous clinical study or as a therapeutic agent.

3. The participant has gout or secondary hyperuricemia (e.g., due to myeloproliferative disorder, or organ transplant) or has experienced a gout flare.

4. The participant has a history of xanthinuria.

5. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.

6. The participant has a history of hypersensitivity or allergies to febuxostat or nitroglycerine.

7. The participant has hemoglobin <10 g/L at Screening Day -21.

8. The participant has a systolic blood pressure of less than 100 mmHg.

9. The participant has a blood pressure of greater than 200/100 at any Screening or Run-in visit.

10. The participant has a history or clinical manifestations of a significant medical condition that might affect his/her ability to complete the study.

11. The participant has any of the following at any Screening or Run-in visit:

1. Resting ST-segment depression ≥1 mm in any lead.

2. Left bundle-branch block.

3. New York Heart Association Class III or IV heart failure.

4. Acute coronary syndrome or a coronary revascularization procedure within 3 months of Screening.

5. Wolff-Parkinson-White syndrome.

6. Pacemaker or implantable cardioverter defibrillator.

7. Arrhythmias (i.e., SVT, atrial fibrillation/flutter, VT, or rate related bundle branch blocks).

8. Left ventricular hypertrophy with repolarization abnormalities.

12. The participant has a recent history (within the last 3 months) of myocardial infarction, heart failure, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.

13. The participant has a contraindication for using nitrates (severe anemia, increased intracranial pressure, and those with a known sensitivity or hypersensitivity to nitroglycerin or its ingredients, or other nitrates or nitrites; concomitant use either regularly and/or intermittently, with phosphodiesterase type 5 (PDE5) inhibitors).

14. The participant has unstable angina that:

1. Occurs when the participant is at rest.

2. Is prolonged, usually greater than 20 minutes.

3. Occurs with increasing in intensity, duration, and/or frequency.

4. Responds poorly to nitroglycerin (i.e., does not go away after three doses of nitroglycerin or returns after the nitroglycerin helped at first).

15. The participant is unable to exercise sufficiently to complete ETT due to leg claudication, arthritis, deconditioning, or associated pulmonary disease.

16. The participant has severe or critical valvular disease documented by echocardiogram, or congenital heart disease.

17. The participant has left ventricular ejection fraction (LVEF) less than 35%, as documented by echocardiogram or angiography.

18. The participant has clinically significant cardiac conduction defects (i.e., second- or third-degree atrioventricular block, sick sinus syndrome or a QTc >500 msec) at Day -21.

19. The participant has active acute myocarditis/pericarditis within the 3 months prior to Screening Day -21.

20. The participant has hypertrophic cardiomyopathy.

21. The participant has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level of greater than 2.0 times the upper limit of normal, has active liver disease, or jaundice.

22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit.

23. The participant is required or expected to require excluded medications digoxin and digoxin-containing compounds.

24. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.

25. The participant has participated in another clinical study within the past 30 days.

26. The participant has a history of extracorporeal external counterpulsation treatment for chronic stable angina within 3 months prior to screening visit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director Clinical Science

Role: STUDY_DIRECTOR

Takeda

Locations

Carmichael, California, United States

Fresno, California, United States

Irvine, California, United States

Paramount, California, United States

Sacramento, California, United States

San Diego, California, United States

Tampa, Florida, United States

Dunwoody, Georgia, United States

Suwanee, Georgia, United States

Lexington, Kentucky, United States

City of Saint Peters, Missouri, United States

St Louis, Missouri, United States

Salisbury, North Carolina, United States

Columbus, Ohio, United States

Lyndhurst, Ohio, United States

Oklahoma City, Oklahoma, United States

Tipton, Pennsylvania, United States

San Antonio, Texas, United States

Manassas, Virginia, United States

Port Orchard, Washington, United States

Madison, Wisconsin, United States

Countries

United States

Related Links

http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&fileTypeCode=ULORICPI

Uloric Package Insert

Other Identifiers

U1111-1125-1278

Identifier Type: REGISTRY

Identifier Source: secondary_id

TMX-67_207

Identifier Type: -

Identifier Source: org_study_id